RadNet Q4 total revenue rises 14.8% to USD 547.7 million

Reuters
03/02
<a href="https://laohu8.com/S/RDNT">RadNet</a> Q4 total revenue rises 14.8% to USD 547.7 million

RadNet posted record Q4 2025 revenue of USD 547.7 million, up 14.8%, with adjusted EBITDA of USD 87.7 million, up 16.9%, and an adjusted EBITDA margin of 16.0% (up 29 bps). Adjusted EPS was USD 0.23. On a GAAP basis, Q4 2025 net loss attributable to common stockholders was USD 0.6 million, or USD (0.01) per diluted share. Digital Health Q4 2025 revenue (inclusive of intersegment revenue) was USD 27.9 million, up 48.2%, with adjusted EBITDA of USD 4.9 million, up 8.9%. RadNet said aggregate advanced imaging (MRI, CT and PET/CT) procedural volumes rose 14.1% in Q4 2025, with same-center advanced imaging up 9.6%. For FY 2025, RadNet reported revenue of USD 2.0 billion, up 11.5%, and adjusted EBITDA of USD 300.2 million, up 7.4%. FY 2025 net loss attributable to common stockholders was USD 18.7 million, or USD (0.25) per diluted share. FY 2025 Digital Health revenue (inclusive of intersegment revenue) was USD 92.7 million, up 41.1%, with adjusted EBITDA of USD 15.5 million, up 1.9%; Digital Health ARR at December 31, 2025 was USD 75.4 million. RadNet also issued 2026 guidance, projecting Imaging Center segment revenue of USD 2.3 billion to USD 2.4 billion, adjusted EBITDA of USD 335 million to USD 348 million, and free cash flow of USD 105 million to USD 115 million. Digital Health segment revenue is guided to USD 135 million to USD 145 million, reflecting about USD 16 million from the Gleamer acquisition; RadNet said the deal expands its clinical AI portfolio and that it expects a minimum of four FDA clearances in 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. RadNet Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202603020600PRIMZONEFULLFEED9663617) on March 02, 2026, and is solely responsible for the information contained therein.

應版權方要求,你需要登入查看該內容

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10